NasdaqCM - Delayed Quote USD

Sunshine Biopharma, Inc. (SBFMW)

0.1986
0.0000
(0.00%)
As of May 12 at 4:00:00 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Steve N. Slilaty Ph.D. Chairman, President & CEO 1.29M -- 1952
Mr. Camille Sebaaly CFO & Secretary 352.03k -- 1959
Dr. Abderrazzak Merzouki COO & Director 366.62k -- 1964
Mr. Malek Chamoun Chief Development Officer -- -- 1985
Mr. Michel Roy Chief Commercial Officer -- -- 1968
Mr. Robert G. Ferreira President of Sunshine Bio Investments Inc -- -- 1962

Sunshine Biopharma, Inc.

333 Las Olas Way
CU4 Suite 433
Fort Lauderdale, FL 33301
United States
(954) 330-0684 https://sunshinebiopharma.com
Sector: 
Healthcare
Full Time Employees: 
52

Description

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Corporate Governance

Sunshine Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers